FDA Tweaks Patent Delay Petitions for Drugs
Published Date: 5/21/2026
Notice
Summary
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
Estimated Annual Time Burden
FDA estimates annual respondent burden of 560 hours total: five revision requests of regulatory review period determinations at 100 hours each (500 hours), one due diligence petition at 50 hours, and one due diligence hearing request at 10 hours. FDA estimates no capital or operating costs and based these numbers on the average filings over the past 3 years.
Paperwork Rules for Patent Extensions
If you are a patent holder for a new drug, biologic, medical device, animal drug, food additive, or color additive, FDA is continuing the information-collection requirements (OMB control number 0910-0233) for petitions under 21 CFR part 60. The agency submitted this paperwork collection to OMB for review under the Paperwork Reduction Act and is seeking public comment by June 22, 2026.
No Change to 'Due Diligence' Definition
FDA stated it believes the existing definition of "due diligence" in 21 CFR 60.36(a) is adequate and will not revise that definition in this submission. Petitioners should plan under the current definition, which FDA quotes as the degree of attention, continuous directed effort, and timeliness reasonably expected during a regulatory review period.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
Previous / Next Documents
Previous: 2026-10189 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Adverse Experience/Events With Approved New Animal Drugs
The FDA is asking for approval to keep collecting info about problems with approved new animal drugs, like side effects or manufacturing issues. This helps make sure animal medicines stay safe and effective. Drug companies need to keep reporting these issues, and the public can comment until June 22, 2026. There’s no new cost, just a continuation of current rules.
Next: 2026-10191 — Agency Information Collection Activities; Proposed Information Collection Request; Comment Request; Performance Evaluation Studies on Wastewater Laboratories (Renewal)
The EPA wants to keep checking how well wastewater labs do their tests by renewing a paperwork request that helps them gather info. This affects labs that test water and anyone interested can share their thoughts by July 20, 2026. The renewal keeps things running smoothly without extra costs or big changes, just more time to keep the quality high.